Previous 10 | Next 10 |
23andMe (NASDAQ:ME): Q2 GAAP EPS of -$0.04 beats by $0.07. Revenue of $55.2M (+6.6% Y/Y) misses by $0.51M. Press Release For further details see: 23andMe EPS beats by $0.07, misses on revenue
Second quarter revenue of $55 million Recent addition of telemedicine platform further advances vision of individualized primary care that empowers consumers to live healthier lives SUNNYVALE, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“...
23andMe to Present at Upcoming Virtual Healthcare Conferences PR Newswire SUNNYVALE, Calif. , Nov. 9, 2021 /PRNewswire/ -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading consumer genetics and research company, announced today that management will be...
23andMe (NASDAQ:ME) is scheduled to announce Q2 earnings results on Wednesday, November 10th, before market open. The consensus EPS Estimate is -$0.13 and the consensus Revenue Estimate is $55.71M. Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. In last week...
ACST, OTCQX:ADDYY, ADNT, AER, AFMD, OTCPK:ALIZF, ALT, ARCO, ASC, ATXS, AY, BTAI, BWEN, DTIL, OTCPK:EMRAF, ENR, EOSE, EVGO, FOUR, FVRR, OTCQX:GDNSF, GIB, GMAB, GSL, OTCQX:IFNNY, INVZ, IS, KIO, KRNT, LODE, MCRB, ME, ML, MNDY, MOGO, MSGS, NEON, NMM, NOVN, OTIC, PDSB, OTCPK:PEYUF, PFGC, PRGO, PTE...
23andMe Announces Appointment of Dr. Sandra Hernández to Board of Directors PR Newswire SUNNYVALE, Calif. , Nov. 9, 2021 /PRNewswire/ -- 23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading consumer genetics and research company, today announced the ...
SUNNYVALE, Calif., Nov. 03, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, announced today that it will report financial results for the fiscal year 2022 second quarter after market closes on Wednesday, ...
NBA superstar Kevin Durant is spearheading a $200M IPO for Infinite Acquisition Corp. (NFNTU), a new SPAC that will focus on bringing a sports business, health & wellness firm or other promising company public. Durant’s Thirty Five Ventures and financial firm LionTree filed paperwo...
Shares of 23andMe (NASDAQ: ME) jumped 27.9% in October, according to data from S&P Global Market Intelligence . The consumer genetics and pharmaceutical research company announced an acquisition of the telehealth platform Lemonaid Health for $400 million last month, which is...
SUNNYVALE, Calif., Nov. 01, 2021 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (“23andMe”), a leading consumer genetics and research company, today announced that it has completed its previously-announced acquisition of Lemonaid Health, Inc. (“Lemonaid Health...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial resu...
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy organizations, today announced a new study to help advance research in lung cancer. The focus of the Lun...